Oral care compositions with an anticaries or anticavity effect. Oral care compositions that are have an extract from a species in the Humulus family and an anticaries drug, such as a fluoride ion source. Oral care compositions have fluoride and hops beta acid, such as from an extract from Humulus lupulus. Oral care compositions have a fluoride ion source and a hops beta acid derived from an extract of Humulus lupulus.

Oral care compositions with two or more components with a subtherapeutic anticaries effect, but, in combination, provide a therapeutic anticaries effect. Oral care compositions that are fluoride-free or lower in fluoride content, but have an equivalent or greater anticaries benefit than a composition comprising a therapeutic amount of fluoride ions.

Fluoride-free oral care compositions with an anticaries or anticavity effect. Oral care compositions that are fluoride-free and have an extract from a species in the Humulus family. Oral care compositions that are fluoride-free and have an extract from Humulus lupulus. Oral care compositions that are fluoride-free and have a hops beta acid.

Oral care compositions that have hops beta acid, such as from an extract from a species in the Humulus family, and a metal ion source, such as a tin ion source and/or a zinc ion source. Oral care compositions that have a tin ion source and/or a zinc ion source and one or more hops beta acids, such as from an extract from Humulus lupulus. Oral care compositions have a tin ion source and/or a zinc ion source and a beta acid derived from an extract of Humulus lupulus.

Methods of use of oral care compositions comprising hops. Methods of use of anticavity oral care compositions that are free of fluoride. Methods of use of anticavity toothpaste comprising hops. Methods of use of anticavity toothpaste comprising hops that are free of fluoride. Methods of treatment, reduction, and/or prevention of caries using an oral care composition comprising hops, and optionally fluoride free.

Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXR-NR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells. In addition, compositions and methods for increasing or decreasing the growth rate of hair follicles is disclosed by altering the intracellular pH.

A reduced coenzyme Q.sub.10-containing composition has high water solubility and excellent storage stability. A powder composition contains the reduced coenzyme Q.sub.10, starch octenylsuccinate, and gum Arabic. A method of producing the powder composition includes homogenizing the ingredients in water to obtain an emulsion composition; and drying the composition.

Toothpaste formulations supporting the health, well-being, and/or appearance of a user's skin is described herein, as are coordinated uses of such formulations. Methods of using these formulations to support the beauty, health, well-being, and/or appearance of a user's skin are described. Kits are also identified.

Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXRNR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells. In addition, compositions and methods for increasing or decreasing the growth rate of hair follicles is disclosed by altering the intracellular pH.

The invention relates to a composition comprising melatonin, a metabolite or derivative thereof and coenzyme Q10 and to use thereof for the production of a pharmaceutical or cosmetic composition for the treatment of the skin, said composition potentiating the movement of both molecules into the mitochondrion and facilitating percutaneous absorption, in which both the melatonin and the CoQ10 can reach all of the strata of the skin.